Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

XVIE is a proprietary, additive-free Human amniotic fluid (hAF) based therapy, containing a diverse array of bioactive molecules including growth factors, cytokines, hyaluronic acid, extracellular matrix proteins, and extracellular vesicles including exosomes. Extensive research have shown the ability of Xvie components to support cellular proliferation, angiogenesis, immune regulation, and matrix remodeling which has the potential to reverse underlying cause of hair loss.

In the study, participants will be asked to complete the following:

• Provide basic personal Information
• Provide a Medical & Surgical History
• Follow study requirements to avoid certain medication and treatments
• Complete all study visits and follow-up calls
• Complete self-assessments and treatment use logs
• Allow clinical assessment and photographic documentation of treatment.

All participants have the right to refuse further participation in the study at any time.

Inclusion criteria

• Women aged 28-65 years with self-perceived thinning hair (confirmed by an investigator).
• Ludwig Scale 1 to 2
• Fitzpatrick skin types I to VI.
• Ability and willingness to comply with the study protocol.
• Commitment to using effective contraception throughout the study if of childbearing potential.

Exclusion criteria

• Pregnancy, nursing, or recent initiation of hormone therapy.
• Change in other hair treatments within 3 months prior to the study.
• Known uncontrolled health conditions (e.g., poorly controlled diabetes, hypertension).
• History of hair or scalp disorders that could interfere with study results.
• History of keloid formation or poor wound healing
• History of bleeding and/or clotting disorders